You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
上半年平台業務增長50.6%,知名機構預計藥師幫(9885.HK)2025年營收將超340億
格隆匯 10-19 08:47

10月19日|近日,西南證券對藥師幫(9885.HK)進行研究後,提到其作為院外醫藥B2B平台,“平台+常規自營+首推+創新業務”有望持續帶動業績增長。

作為中國最大的院外醫藥產業數字化綜合服務平台,藥師幫正在加速市場滲透,保持高速增長趨勢。

根據公司2023上半年財報數據顯示,公司平台業務收入4.17億元,同比增長50.6%。上半年公司GMV達到220.41億元人民幣,同比增長34.4%。平台業務的月均可售SKU超330萬個,上游商家數量超7100家,吸引超過58.9萬個買家進行交易。

此外,在盈利狀況上,2023上半年公司經調整後淨利潤首次轉正,達7000萬人民幣以上,運營效率持續改善,資本結構健康,資產質量良好,盈利能力穩步提升。

對此,招銀國際發佈研報指出,看好藥師幫通過B2B院外醫藥數字化解決方案連接和賦能產業鏈參與者、提供安全高效的交易及服務平台的增長潛力,給予藥師幫“買入”評級,目標價為57.97港元。

據招銀國際預計,2022-2025年藥師幫收入將以34%的複合增長率增長,其中2023E/ 2024E/ 2025E的收入將分別為179.02億元/249.60億元/340.30億元,同比增長25.4%/ 39.4%/ 36.3%,non-IFRS調整後淨利潤分別為1.79億元/7.16億元/14.15億元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account